A61K 39/107
Vibrio
Official title: {Vibrio}
A61K39/107 (Vibrio) appears on 146 US grants and 202 published applications in this corpus.
Search patents in A61K- Granted patents
- 146
- Published applications
- 202
- Assignees
- 125
- Inventors
- 416
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 6 | 0 |
| 1998 | 3 | 0 |
| 1999 | 6 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 0 | 8 |
| 2003 | 4 | 1 |
| 2004 | 2 | 3 |
| 2005 | 2 | 3 |
| 2006 | 3 | 7 |
| 2007 | 0 | 6 |
| 2008 | 2 | 6 |
| 2009 | 2 | 2 |
| 2010 | 3 | 7 |
| 2011 | 1 | 2 |
| 2012 | 1 | 6 |
| 2013 | 1 | 7 |
| 2014 | 10 | 15 |
| 2015 | 3 | 13 |
| 2016 | 7 | 11 |
| 2017 | 3 | 16 |
| 2018 | 6 | 7 |
| 2019 | 10 | 9 |
| 2020 | 6 | 19 |
| 2021 | 7 | 16 |
| 2022 | 14 | 5 |
| 2023 | 8 | 9 |
| 2024 | 3 | 10 |
| 2025 | 6 | 7 |
| 2026 | 2 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ostrich antibody for bacterial infectious diseases3 Mar 2026US 12,564,624 B2Ostrich Pharma KK
- Serum free intracellular pathogen vaccine3 Mar 2026US 12,564,626 B2Intervet Inc.
- Compositions and methods18 Nov 2025US 12,472,245 B2CHAIN Biotechnology Limited
- Bacterial vaccine2 Sep 2025US 12,403,187 B2Bellevacc AS
- Methods and compositions related to the next generation vaccine17 Jun 2025US 12,331,085 B2University of Kansas
- Potentiation of an innate immune response in mollusks27 Aug 2026US 2026/0248908 A1
- Methods of vaccine administration to salmonids30 Jul 2026US 2026/0216310 A1Zoetis Services LLC
- Expression of antigen-adjuvant fusion subunit proteins in diatoms, and methods of generation and use thereof16 Jul 2026US 2026/0200994 A1PhycoVax LLC
- Bacterial vaccine9 Jul 2026US 2026/0191942 A1Bellevacc AS
- Serum free intracellular pathogen vaccine11 Jun 2026US 2026/0158132 A1Intervet Inc.
Most cited
By later US patents
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004
- Antigen library immunization76US 6,541,011 B2Maxygen, Inc. · 2003
- Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli35US 4,411,888 AUniversity of Rochester · 1983
- Vibrio cholerae strain CVD103Hg.sup.r, method of making same, and vaccines derived therefrom35US 5,399,494 AThe University of Maryland System · 1995
- Polynucleotide formula against porcine reproductive and respiratory pathologies31US 6,207,165 B1Merial Limited · 2001